Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference (Transcript)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference Call December 7, 2020 8:30 AM ET Company Participants Doug Ingram - President and Chief Executive Officer Gilmore O’Neill - Executive Vice President, R&D Conference Call Participants Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Gena Wang - Barclays Alethia Young - Cantor Brian Skorney - Baird Anupam Rama - JPMorgan Matthew Harrison - Morgan Stanley Tyler Va ...